Aberrant CCND1 copies and cyclin D1 mRNA expression do not result in the production of functional cyclin D1 protein in anaplastic large cell lymphoma

Histology and Histopathology

Volumn 24, Issue 8, 2009, Pages 1035-1048

  Bobos, Mattheos ^a   Kotoula, Vassiliki ^a   Kaloutsi, Vassiliki ^a   Karayannopoulou, Georgia ^a   Papadimitriou, Constantine S ^a   Kostopoulos, Ioannis ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

ALCL; Cyclin D1; Double staining; In situ hybridization; Polysomy 11q13; TROP2

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CD30 ANTIGEN; CYCLIN D1; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; INDOLE DERIVATIVE; MESSENGER RNA; RHODAMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHROMOSOME 11; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD30; CHILD; CHROMOSOMES, HUMAN, PAIR 11; CYCLIN D1; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GENE DOSAGE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; RHODAMINES; RNA, MESSENGER; YOUNG ADULT;

EID: 69149102135     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Aguilera N.S., Bijwaard K.E., Duncan B., Krafft A.E., Chu W.S., Abbondanzo S.L., Lichy J.H. and Taubenberger J.K. (1998). Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. Am. J. Pathol. 153, 1969-1976
2. Alavi S., Namazie A., Calcaterra T., Wang M. and Srivatsan E.S. (1999). Clinical application of fluorescence in situ hybridization for chromosome 11q13 analysis in head and neck cancer. Laryngoscope 109, 874-879.
3. Alberts B., Johnson A., Lewis J., Raff M., Roberts K. and Walter P. (2002). Molecular biology of the cell. 4th ed. Garland Science. New York.
4. Amin H.M., Medeiros L.J., Ma Y., Feretzaki M., Das P., Leventaki V., Rassidakis G.Z., O'Connor S.L., McDonnell T.J. and Lai R. (2003). Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 21, 5399-5407.
5. Athanasiou E., Kotoula V., Hytiroglou P., Kouidou S., Kaloutsi V. and Papadimitriou C.S. (2001). In situ hybridization and reverse transcription-polymerase chain reaction for cyclin D1 mRNA in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues. Mod. Pathol. 14, 62-71.
6. Athanasiou E., Kaloutsi V., Kotoula V., Hytiroglou P., Kostopoulos I., Zervas C., Kalogiannidis P., Fassas A., Christakis J.I. and Papadimitriou C.S. (2001). Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am. J. Clin. Pathol. 116, 535-542.
7. Benzeno S. and Diehl J.A. (2004). C-terminal sequences direct cyclin D1-CRM1 binding. J. Biol. Chem. 279, 56061-56066.
8. Cataldo K.A., Jalal S.M., Law M.E., Ansell S.M., Inwards D.J., Fine M., Arber D.A., Pulford K.A. and Strickler J.G. (1999). Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am. J. Surg. Pathol. 23, 1386-1392.
9. Cheuk W., Wong K.O.Y., Wong C.S.C. and Chan J.K.C. (2004). Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am. J. Surg. Pathol. 28, 801-807.
10. Delsol G., Ralfkiaer E., Stein H., Wright D. and Jaffe E.S. (2001). Anaplastic large cell lymphoma. In: Pathology & genetics. Tumors of haematopoietic and lymphoid tissues. Jaffe E.S., Harris N.L., Stein H. and Vardiman J.W. (eds). IARC Press. Lyon pp 230-235.
11. Drexler H.G., Gignac S.M., von Wasielewski R., Werner M. and Dirks W.G. (2000). Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14, 1533-1559.
12. Elenitoba-Johnson K.S., Bohling S.D., Jenson S.D., Lin Z., Monnin K.A. and Lim M.S. (2002). Fluorescence PCR quantification of cyclin D1 expression. J. Mol. Diagn. 4, 90-96.
13. Foijer F., Wolthuis R.M.F., Doodeman V., Medema R.H and Riele H. (2005). Mitogen requirement for cell cycle progression in the absence of pocket protein activity. Cancer Cell 8, 455-466.
14. Fornaro M., Dell'Arciprete R., Stella M., Bucci C., Nutini M., Capri M.G. and Alberti S. (1995). Cloning of the gene encoding Trop-2, a cellsurface glycoprotein expressed by human carcinomas. Int. J. Cancer 62, 610-618.
15. Fu M., Wang C., Li Z., Sakamaki T. and Pestell R.G. (2004). Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 145, 5439-5447.
16. Greer J.P., Kinney M.C. and Loughran T.P. (2001). Hematology. Am. Soc. Hematl. Educ. Program 259-281.
17. Hosokawa Y. and Arnold A. (1998). Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allelespecific expression. Genes Chromosomes Cancer 22, 66-71.
18. Hunter T. and Pines J. (1994). Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79, 573-582.
19. Kanavaros P., Bai M., Stefanaki K., Poussias G., Rontogianni D., Zioga E., Gorgoulis V. and Agnantis N.J. (2001). Immunohistochemical expression of p53, mdm2, p21/Waf-1, rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Histol. Histopathol. 16, 377-386.
20. Kaneko Y., Frizzera G., Edamura S., Maseki N., Sakurai M., Komada Y., Sakurai M., Tanaka H., Sasaki M., Suchi T., Kikuta A., Wakasa H., Hojo H. and Mizutani S. (1989). A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 73, 806-813.
21. Kristt D., Turner I., Koren R., Ramadan E. and Gal R. (2000). Overexpression of cyclin D1 mRNA in colorectal carcinomas and relationship to clinicopathological features: An in situ hybridization analysis. Pathol. Oncol. Res. 6, 65-70.
22. Lesage D., Troussard X. and Sola B. (2005). The enigmatic role of cyclin D1 in multiple myeloma. Int. J. Cancer 115, 171-176.
23. Leventaki V., Drakos E., Medeiros L.J., Lim M.S., Elenitoba-Johnson K.S., Claret F.X. and Rassidakis G.Z. (2007). NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood 110, 1621-1630.
24. Lin L., Hicks D., Xu B., Sigel J.E., Bergfeld W.F., Montgomery E., Fisher C., Hartke M., Tubbs R. and Goldblum J.R. (2005). Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma. Mod. Pathol. 18, 705-709.
25. Mao X., Orchard G., Lillington D.M., Russell-Jones R., Young B.D. and Whittaker S. (2003). Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 37, 176-185.
26. Mao X., Orchard G., Vonderheid E.C., Nowell P.C., Bagot M., Bensussan A., Russell-Jones R., Young B.D. and Whittaker S.J. (2006). Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J. Invest. Dermatol. 126, 1388-1395.
27. Martínez-Ramírez A., Cigudosa J.C., Maestre L., Rodríguez-Perales S., Haralambieva E., Benítez J. and Roncador G. (2004). Simultaneous detection of the immunophenotypic markers and genetic aberrations on routinely processed paraffin sections of lymphoma samples by means of the FICTION technique. Leukemia 18, 348-353.
28. Masciullo V., Scambia G., Marone M., Giannitelli C., Ferrandina G., Bellacosa A., Benedetti Panici P. and Mancuso S. (1997). Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int. J. Cancer 74, 390-395.
29. Mason D.Y., Bastard C., Rimokh R., Dastugue N., Huret J.L., Kristoffersson U., Magaud J.P., Nezelof C., Tilly H., Vannier J.P., (1990). CD30-positive large cell lymphomas (Ki-1 lymphoma) are associated with a chromosomal translocation involving 5q35. Br. J. Haematol. 74, 161-168.
30. Medeiros L.J. and Elenitoba-Johnson K.S. (2007). Anaplastic large cell lymphoma. Am. J. Clin. Pathol. 127, 707-722.
31. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K., Shapiro D.N., Look A.T. and Saltman D.L. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284.
32. Ohmachi T., Tanaka F., Mimori K., Inoue H., Yanaga K. and Mori M. (2006). Clinical significance of TROP2 expression in colorectal cancer. Clin. Cancer Res. 12, 3057-3063.
33. Ott G., Katzenberger T., Siebert R., DeCoteau J.F., Fletcher J.A., Knoll J.H., Kalla J., Rosenwald A., Ott M.M., Weber-Matthiesen K., Kadin M.E. and Müller-Hermelink H.K. (1998). Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer 22, 114-121.
34. Rassidakis G.Z., Goy A., Medeiros L.J., Jiang Y., Thomaides A., Remache Y., Cabanillas F., Sarris A.H. and Gilles F. (2003). Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res. 9, 2213-2220.
35. Rassidakis G.Z., Lai R., Herling M., Cromwell C., Schmitt-Graeff A. and Medeiros L.J. (2004). Retinoblastoma protein is frequently abscent or phosphorylated in anaplastic large-cell lymphoma. Am. J. Pathol. 164, 2259-2267.
36. Rimokh R., Berger F., Bastard C., Klein B., French M., Archombaud E., Rouault J-P., Santa Lucia B., Duret L., Vuillaume M., Coiffier B., Bryon P-A. and Magaud J-P. (1989). A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ("Ki-1 lymphoma"). Br. J. Haematol. 71, 31-36.
37. Rimokh R., Berger F., Bastard C., Klein B., French M., Archimbaud E., Rouault J.P., Santa Lucia B., Duret L. and Vuillaume M. (1994). Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 83, 3689-3696.
38. Ronchetti D., Finelli P., Richelda R., Baldini L., Rocchi M., Viggiano L., Cuneo A., Bogni S., Fabris S., Lombardi L., Maiolo A.T. and Neri A. (1999). Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 93, 1330-1337.
39. Sallinen S.L., Sallinen P.K., Kononen J.T., Syrjäkoski K.M., Nupponen N.N., Rantala I.S., Helén P.T., Helin H.J. and Haapasalo H.K. (1999). Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis. J. Pathol. 188, 289-293.
40. Sherr C. and Roberts J. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512.
41. Sicinska E., Aifantis I., Le Cam L., Swat W., Borowski C., Yu Q., Ferrando A.A., Levin S.D., Geng Y., von Boehmer H. and Sicinski P. (2003). Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-461.
42. Specht K., Kremer M., Müller U., Dirnhofer S., Rosemann M., Höfler H., Quintanilla-Martinez L. and Fend F. (2002). Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin. Cancer Res. 8, 2902-2911.
43. Specht K., Haralambieva E., Bink K., Kremer M., Mandl-Weber S., Koch I., Tomer R., Höfler H., Schuuring E., Kluin P.M., Fend F. and Quintanilla-Martinez L. (2004). Different mechanisms if cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104, 1120-1126.
44. Stein H., Mason D.Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R. and Lennert K (1985). The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66, 848-858.
45. Stein H., Foss H.D., Dürkop H., Marafioti T., Delsol G., Pulford K., Pileri S. and Falini B. (2000). CD30+ anaplastic large cell lymphoma: a review of it's histopathologic genetic, and clinical features. Blood 96, 3681-3695.
46. Sumrejkanchanakij P., Tamamori-Adachi M., Matsunaga Y., Eto K. and Ikeda M.A. (2003). Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons. Oncogene 22, 8723-8730.
47. Sun F., Fu H., Liu Q., Tie Y., Zhu J., Xing R., Sun Z. and Zheng X. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 582, 1564-1568.
48. Terrinoni A., Dell'Arciprete R., Fornaro M., Stella M. and Alberti S. (2001). Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cells. Genes Chromosomes Cancer 31, 209-220.
49. Thompson M.A., Stumph J., Henrickson S.E., Rosenwald A., Wang Q., Olson S., Brandt S.J., Roberts J., Zhang X., Shyr Y. and Kinney M.C. (2005). Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 36, 494-504.
50. Turturro F., Frist A.Y., Arnold M.D., Seth P. and Pulford K. (2001). Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27(Kip1). Oncogene 27:4466-4475.
51. Wang J., Day R., Dong Y., Weintraub S.J. and Michel L. (2008). Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol. Cancer Ther. 7, 280-285.
52. Wiestner A., Tehrani M., Chiorazzi M., Wright G., Gibellini F., Nakayama K., Liu H., Rosenwald A., Muller-Hermelink H.K., Ott G., Chan W.C., Greiner T.C., Weisenburger D.D., Vose J., Armitage J.O., Gascoyne R.D., Connors J.M., Campo E., Montserrat E., Bosch F., Smeland E.B., Kvaloy S., Holte H., Delabie J., Fisher R.I., Grogan T.M., Miller T.P., Wilson W.H., Jaffe E.S. and Staudt L.M. (2007). Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 109, 4599-4606.
53. Wellmann A., Doseeva V., Butscher W., Raffeld M., Fukushima P., Stetler-Stevenson M. and Gardner K. (1997). The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J. 11, 965-972.
54. Wu M.Y., Zhuang C.X., Yang H.X. and Liang Y.R. (2004). Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. World J. Gastroenterol.15, 476-480.
55. Yatabe Y., Suzuki R., Matsuno Y., Tobinai K., Ichinohazama R., Tamaru J., Mizoguchi Y., Hashimoto Y., Yamaguchi M., Kojima M., Uike N., Okamoto M., Isoda K., Ichimura K., Morishima Y., Seto M., Suchi T. and Nakamura S. (2001). Morphological spectrum of cyclin D1-positive mantle cell lymphoma: Study of 168 cases. Pathol. Int. 51, 747-761.
56. Zettl A., Rüdiger T., Konrad M.A., Chott A., Simonitsch-Klupp I., Sonnen R., Müller-Hermelink H.K. and Ott G. (2004). Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am. J. Pathol. 164, 1837-1848.